Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Master Gene Regulator Could be New Target for Schizophrenia Treatment

By Drug Discovery Trends Editor | May 26, 2015

Model for presynaptic effects of miR-137, a specific microRNA, or short stretch of RNA.  Image courtesy of the researchers.Researchers at MIT’s Picower Institute for Learning and Memory have identified a master genetic regulator that could account for faulty brain functions that contribute to schizophrenia.
 
The work, reported in the advance online publication of Nature Neuroscience, may one day lead to new strategies for treating schizophrenia and other diseases caused by malfunctioning synapses, the connections among neurons, said co-author Li-Huei Tsai, director of the Picower Institute and the Picower Professor of Neuroscience at MIT.
 
Messenger RNA (mRNA) translates DNA’s genetic information into codes for proteins. A recently discovered class of noncoding RNA molecules, short stretches of RNA called microRNAs (miRNAs) has been shown to interact with mRNA and block protein production.
 
More than 3,000 miRNAs have been found in the human genome. A single miRNA can regulate the activity of hundreds of genes, thus impacting entire cellular networks.
 
Genetic variations in the gene encoding a particular microRNA — miRNA-137 — have been linked with an increased risk for schizophrenia. While schizophrenia is tied to multiple genes, “a more complete picture of miRNAs may improve our understanding of the molecular mechanisms underlying schizophrenia,” Tsai says.
 
Exactly how genetic variations impact miRNA-137 levels — and effects of miRNA-137 in the brain — is unclear. “It’s important to understand how abnormal levels of miRNA-137 impact cellular function,” says co-author Sandra Siegert, a postdoc in the Picower Institute.
 
Siegert found that in reprogrammed neurons from human fibroblasts of diseased patients, microRNA-137 was increased. This was, in turn, tied to presynaptic defects and impaired synaptic plasticity and cognitive dysfunction. This was a surprise, she says, because although schizophrenia is considered “a disease of the synapse,” nobody had ever shown that microRNAs could influence the mechanism through which neurotransmitters are released at the synapse.
 
“This work demonstrates that miRNAs directly impact synaptic proteins,” Tsai says. “This shows a master regulator role for MiRNA-137 as an exciting common regulator of presynaptic function.” The study proves that “just by down-regulating miRNA-137, we were able to improve synaptic transmission in neurons,” Siegert says. “This is very promising, and shows the beneficial effects” of manipulating miRNA-137.
 
MiRNAs also have been found to be a gateway for environmental factors’ influence on cellular mechanisms. For instance, drug abuse or stress can alter miRNA levels. “If we knew which environmental factors affected MiRNA-137, there might be a simple approach to tweaking it. If genetic testing showed an individual was a carrier of the risk-related variation of the MiRNA-137 gene, avoiding an unhealthy lifestyle or drugs in a critical phase of brain development might prevent disease onset,” Siegert says.
 
This work is supported by the Simons Center for the Social Brain and the National Institutes of Health.
 
Source: MIT

Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE